RESEARCH PAPER
Effects of alizarin, betulin, curcumin, diosmin , linalool, menthofuran, α-terpineol, theobromine, β-thujaplicin and vanillin against maximal electroshock-induced seizures in mice
 
More details
Hide details
1
Department of Pathophysiology, Medical University, Lublin, Poland;
2
Isobolographic Analysis Laboratory, Institute of Rural Health, Lublin, Poland
3
Department of Pharmacognosy, Medical University, Wrocław, Poland
4
Department of Public Health, Institute of Rural Health, Lublin, Poland
CORRESPONDING AUTHOR
Jarogniew J. Łuszczki   

Department of Pathophysiology, Medical University, Jaczewskiego 8, 20-090 Lublin, Poland
 
J Pre Clin Clin Res. 2013;7(1):40–42
KEYWORDS
ABSTRACT
Introduction and objective:
The study was aimed at performing the anticonvulsant screening test to select some naturally occurring substances isolated from herbs and medicinal plants that could suppress seizures in the maximal electroshock (MES)-induced tonic seizure model in mice.

Material and Methods:
The screening test was performed for 10 natural substances (alizarin, betulin, curcumin, diosmin, linalool, menthofuran, α-terpineol, theobromine, β-thujaplicin and vanillin) administered intraperitoneally in a constant dose of 300 mg/kg at various pre-treatment times (15, 30, 60 and 120 min.) before the MES test.

Results:
Only α-terpineol and vanillin produced a 12.5% protection against MES-induced tonic seizures in mice, when administered i.p. at 120 and 60 min., prior to the MES test, respectively. In contrast, the remaining substances (alizarin, betulin, curcumin, diosmin, linalool, menthofuran, theobromine and β-thujaplicin) produced no anti-convulsant activity after their i.p. administration to mice.

Conclusions:
α-Terpineol and vanillin are worth considering as potentially favorable compounds in experimental epileptology.

 
REFERENCES (24)
1.
Abelson PH. Medicine from plants. Science 1990; 247: 513.
 
2.
Heinrich M, Gibbons S. Ethnopharmacology in drug discovery: an analysis of its role and potential contribution. J Pharm Pharmacol. 2001; 53: 425–432.
 
3.
Heinrich M. Ethnobotany and its role in drug development. Phytother Res. 2000; 14: 479–488.
 
4.
Heinrich M. Ethnobotany and natural products: the search for new molecules, new treatments of old diseases or a better understanding of indigenous cultures? Curr Top Med Chem. 2003; 3: 141–154.
 
5.
Raza M, Shaheen F, Choudhary MI, Suria A, Rahman AU, Sombati S, DeLorenzo RJ. Anticonvulsant activities of the FS-1 subfraction isolated from roots of Delphinium denudatum. Phytother Res. 2001; 15: 426–430.
 
6.
Blanco MM, Costa CA, Freire AO, Santos JG Jr, Costa M. Neurobehavioral effect of essential oil of Cymbopogon citratus in mice. Phytomedicine 2009; 16: 265–270.
 
7.
Liao WP, Chen L, Yi YH, Sun WW, Gao MM, Su T, Yang SQ. Study of antiepileptic effect of extracts from Acorus tatarinowii Schott. Epilepsia 2005; 46 (Suppl 1): 21–24.
 
8.
Mandegary A, Arab-Nozari M, Ramiar H, Sharififar F. Anticonvulsant activity of the essential oil and methanolic extract of Bunium persicum (Boiss). B. Fedtsch. J Ethnopharmacol. 2012; 140: 447–451.
 
9.
Mandegary A, Sharififar F, Abdar M, Arab-Nozari M. Anticonvulsant activity and toxicity of essential oil and methanolic extract of Zhumeria majdae Rech, a unique Iranian plant in mice. Neurochem Res. 2012; 37: 2725–2730.
 
10.
Pourgholami MH, Kamalinejad M, Javadi M, Majzoob S, Sayyah M. Evaluation of the anticonvulsant activity of the essential oil of Eugenia caryophyllata in.
 
11.
Pourgholami MH, Majzoob S, Javadi M, Kamalinejad M, Fanaee GH, Sayyah M. The fruit essential oil of Pimpinella anisum exerts anticonvulsant effects in mice. J Ethnopharmacol. 1999; 66: 211-215.
 
12.
Sayyah M, Nadjafnia L, Kamalinejad M. Anticonvulsant activity and chemical composition of Artemisia dracunculus L. essential oil. J Ethnopharmacol. 2004; 94: 283–287.
 
13.
Sayyah M, Valizadeh J, Kamalinejad M. Anticonvulsant activity of the leaf essential oil of Laurus nobilis against pentylenetetrazole- and maximal electroshock-induced seizures. Phytomedicine, 2002; 9: 212–216.
 
14.
Wahab A, Ul Haq R, Ahmed A, Khan RA, Raza M. Anticonvulsant activities of nutmeg oil of Myristica fragrans. Phytother Res. 2009; 23: 153–158.
 
15.
Łuszczki JJ, Głowniak K, Czuczwar SJ. Imperatorin enhances the protective activity of conventional antiepileptic drugs against maximal electroshock-induced seizures in mice. Eur J Pharmacol. 2007; 574: 133–139.
 
16.
Łuszczki JJ, Głowniak K, Czuczwar SJ. Time-course and dose-response relationships of imperatorin in the mouse maximal electroshock seizure threshold model. Neurosci Res. 2007; 59: 18–22.
 
17.
Łuszczki JJ, Wojda E, Andres-Mach M, Cisowski W, Glensk M, Glowniak K, Czuczwar SJ. Anticonvulsant and acute neurotoxic effects of imperatorin, osthole and valproate in the maximal electroshock seizure and chimney tests in mice: a comparative study. Epilepsy Res. 2009; 85: 293–299.
 
18.
Łuszczki JJ, Wojda E, Raszewski G, Głowniak K, Czuczwar SJ. Influence of imperatorin on the anticonvulsant activity and acute adverse-effect profile of lamotrigine in maximal electroshock-induced seizures and chimney test in mice. Pharmacol Rep. 2008; 60: 566–573.
 
19.
Łuszczki JJ, Andres-Mach M, Gleńsk M, Skalicka-Woźniak K. Anticonvulsant effects of four linear furanocoumarins, bergapten, imperatorin, oxypeucedanin, and xanthotoxin, in the mouse maximal electroshock-induced seizure model: a comparative study. Pharmacol Rep. 2010; 62: 1231–1236.
 
20.
Łuszczki JJ, Włodarczyk M, Gleńsk M, Marzęda E, Durmowicz D, Florek-Łuszczki M. Effects of various naturally occurring compounds (arbutin, esculetin, esculin, ellagic acid, gallic acid, hesperidine, piperitol, piperonal, quercetin, thymoquinone and ursolic acid) against maximal electroshock-induced seizures in mice – a part I of the screening test. Curr Issues Pharm Med Sci. In Press.
 
21.
Löscher W, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 1991; 8: 79–94.
 
22.
Brodie MJ, Schachter SC. Fast Facts. Epilepsy, 2nd ed. Oxford, Health Press, 2001.
 
23.
Stables JP, Kupferberg HJ. Chapter 16 – The NIH Anticonvulsant DrugeDevelopment (ADD) Program: preclinical anticonvulsant screening project. In: Avanzini G, Regesta G, Tanganelli P, Avoli M, eds. Molecular and cellular targets for anti-epileptic drugs. London, John Libbey, 1997. p. 191–198.
 
24.
White HS, Woodhead JH, Wilcox KS, Stables JP, Kupferberg HJ, Wolf HH. Discovery and preclinical development of antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs. 5th ed. Philadelphia, Lippincott Williams & Wilkins, 2002. p. 36–48.
 
eISSN:1898-7516
ISSN:1898-2395